HomeCompareTKBIF vs PLD

TKBIF vs PLD: Dividend Comparison 2026

TKBIF yields 1.58% · PLD yields 3.18%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PLD wins by $6.48M in total portfolio value
10 years
TKBIF
TKBIF
● Live price
1.58%
Share price
$7.30
Annual div
$0.12
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$22.0K
Annual income
$174.62
Full TKBIF calculator →
PLD
PLD
● Live price
3.18%
Share price
$128.78
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$6.50M
Annual income
$5,256,436.18
Full PLD calculator →

Portfolio growth — TKBIF vs PLD

📍 PLD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTKBIFPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TKBIF + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TKBIF pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TKBIF
Annual income on $10K today (after 15% tax)
$134.02/yr
After 10yr DRIP, annual income (after tax)
$148.43/yr
PLD
Annual income on $10K today (after 15% tax)
$270.62/yr
After 10yr DRIP, annual income (after tax)
$4,467,970.75/yr
At 15% tax rate, PLD beats the other by $4,467,822.33/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TKBIF + PLD for your $10,000?

TKBIF: 50%PLD: 50%
100% PLD50/50100% TKBIF
Portfolio after 10yr
$3.26M
Annual income
$2,628,305.40/yr
Blended yield
80.55%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

TKBIF
No analyst data
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+5.6% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TKBIF buys
0
PLD buys
0
No recent congressional trades found for TKBIF or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTKBIFPLD
Forward yield1.58%3.18%
Annual dividend / share$0.12$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$22.0K$6.50M
Annual income after 10y$174.62$5,256,436.18
Total dividends collected$1.7K$6.37M
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: TKBIF vs PLD ($10,000, DRIP)

YearTKBIF PortfolioTKBIF Income/yrPLD PortfolioPLD Income/yrGap
1← crossover$10,858$157.67$11,255$555.24$397.00PLD
2$11,778$159.99$13,062$1,018.59$1.3KPLD
3$12,764$162.20$15,903$1,926.67$3.1KPLD
4$13,822$164.29$20,839$3,823.32$7.0KPLD
5$14,956$166.26$30,464$8,166.08$15.5KPLD
6$16,171$168.13$52,054$19,457.30$35.9KPLD
7$17,473$169.90$109,886$54,188.93$92.4KPLD
8$18,868$171.57$304,030$186,451.18$285.2KPLD
9$20,361$173.14$1,166,125$840,813.32$1.15MPLD
10$21,961$174.62$6,504,190$5,256,436.18$6.48MPLD

TKBIF vs PLD: Complete Analysis 2026

TKBIFStock

Takara Bio Inc., together with its subsidiaries, engages in bioindustry, contract development and manufacturing organization (CDMO), and gene therapy businesses in Japan, China, rest of Asia, the United States, Europe, and internationally. The company sells reagents and instruments, including genetic research reagents and testing kits; products related to coronavirus testing comprising in vitro diagnostics that detect viruses; analytical reagents; single-cell analysis systems; gene expression research reagents; fluorescent proteins series; genome-editing research reagents; iPS cell research reagents; and products for stem cell culturing and induction of differentiation under the TaKaRa, Clontech, and Cellartis brand names. It also provides contract services for regenerative medicine products, such as manufacturing of viral vectors and gene-transduced cells, quality and safety testing, and cell banking; and contract services for gene analysis and testing, including sequencing, intestinal flora analysis, comprehensive analysis of cancer-associated genes, and cell line creation through genome editing. In addition, the company is involved in developing platform technology for biologics development in areas, such as gene therapy. The company was incorporated in 2002 and is based in Kusatsu, Japan. Takara Bio Inc. is a subsidiary of Takara Holdings Inc.

Full TKBIF Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this TKBIF vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TKBIF vs SCHDTKBIF vs JEPITKBIF vs OTKBIF vs KOTKBIF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.